Nucleic Acid Hybrids as Advanced Antibacterial Nanocarriers

Abstract

<jats:p>Conventional antibiotic therapy is often challenged by poor drug penetration/accumulation at infection sites and poses a significant burden to public health. Effective strategies to enhance the therapeutic efficacy of our existing arsenal include the use of nanoparticulate delivery platforms to improve drug targeting and minimize adverse effects. However, these nanocarriers are often challenged by poor loading efficiency, rapid release and inefficient targeting. Nucleic acid hybrid nanocarriers are nucleic acid nanosystems complexed or functionalized with organic or inorganic materials. Despite their immense potential in antimicrobial therapy, they are seldom utilized against pathogenic bacteria. With the emergence of antimicrobial resistance and the associated complex interplay of factors involved in antibiotic resistance, nucleic acid hybrids represent a unique opportunity to deliver antimicrobials against resistant pathogens and to target specific genes that control virulence or resistance. This review provides an unbiased overview on fabricating strategies for nucleic acid hybrids and addresses the challenges of pristine oligonucleotide nanocarriers. We report recent applications to enhance pathogen targeting, binding and control drug release. As multifunctional next-generational antimicrobials, the challenges and prospect of these nanocarriers are included.</jats:p>

Synthesizing the biochemical and semiconductor worlds: the future of nucleic acid nanotechnology

“…By providing a unique bridge between the micro-and nanoscales, NAN will enable countless advances in biophysical chemistrybeyond the emerging products we have already discussed: for example, the ability to spatially organize antibacterial agents has potential to improve antibiotics. 99,100 The vast toolbox of colloidal self-assembly has already benefitted from NAN 101 further integration of these technologies could enable programmable, self-organizing, and self-regulating vesical micro-reactors.…”

Combating Antibiotic Resistance in Bacteria: The Development of Novel Therapeutic Strategies

“…Nucleic acid nanostructures have been found to have anti-inflammatory characteristics, which are important in a variety of infections, including applications in topical wounds. 134 Ex. Murepavadin and polymyxin B were combined in a collaborative work between industry and academics to create a chain of peptidomimetic hybrids (murepavadin is a -turn peptidomimetic of protegrin I).…”

“…The effectiveness of antibacterial platforms may be created by employing nucleic acid hybrid platforms to address these challenges and acquire better knowledge of in vivo action. 134 This combination was the addition of a second interaction including lipid A via the polymyxin piece to infections of the joints DSTA4637S mechanism of action, which interacts with the outer membrane proteins of GN bacteria. A recent experiment performed by Polyphor, (a Swiss company), has moved one of the most powerful chimeras to pre-clinical investigations under the POL7306 designation.…”

DNA Nanogel for Cancer Therapy

“…[ 9 ] There have been a lot of reports on various drug delivery systems, among which, DNA nanogels based on pure DNA has offered an outstanding performance. [ 10,11 ]…”